UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one): __ Form 10-KSB __ Form 20-F X Form 10-QSB __ Form N-SAR
--
For period ended: December 31, 1999
[ ] Transition Report on Form 10-K and Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q and Form 10-QSB
[ ] Transition Report on Form N-SAR
For the transition period ended
SEC File Number 0-11472
CUSIP Number - 09061T 50 90
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the
item(s) to which the notification
relates:_________________________________________
PART I-REGISTRANT INFORMATION
BIOMUNE SYSTEMS, INC.
- --------------------------------------
Full Name of Registrant
2401 South Foothill Dr.
Salt Lake City, Utah 84109
(801) 466-3441
- --------------------------------------
Address and telephone number of
principal executive office
PART II-RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed.
(Check appropriate box)
[X] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition
report on Forms 10-K, 10-KSB, 20-F, 11-K, or Form N-SAR, or portion thereof will
be filed on or before the 15th calendar day following the prescribed due date;
or
1
<PAGE>
the subject quarterly report or transition report on Form 10-Q, 10-QSB,
or portion thereof will be filed on or before the fifth calendar day following
the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III-NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 10-KSB,
11-K, 20-F 10-Q, 10-QSB, N-SAR or the transition report portion thereof, could
not be filed within the prescribed time period.
The quarterly report of the registrant on Form 10-QSB could not be
filed because of delays encountered in finalizing the financial and other
information needed to complete the report.
PART IV-OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Michael G. Acton, CEO (801) 466-3441
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) or
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months (or for such shorter period that the
registrant was required to file such report(s)) been filed? If the answer is no,
identify report(s).
X Yes __ No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
__ Yes X No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
2
<PAGE>
BIOMUNE SYSTEMS, INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date February 14, 2000 By: /s/ Michael G. Acton
---------------------------------
Michael G. Acton, Chief Executive Officer
